home · filing · 0001654954-22-000428
8-K filed January 13, 2022, 6:59 PM ET
ticker DRMA
CIK 0001853816
leadership
confidence high
sentiment neutral
materiality 0.20
Dermata appoints Brittany Bradrick to Board and Audit Committee
Dermata Therapeutics, Inc.
Board expanded from 7 to 8; Bradrick appointed as Class II director effective Jan 12, 2022.
Bradrick brings over 25 years life science finance/strategy experience; currently CFO of Neurelis.
Received option to purchase 10,000 shares at $1.50, vesting monthly over 12 months.
Dr. Steven Mento steps down from Audit Committee but stays on Board and Nominating Committee.
No family relationships or transactions requiring disclosure with other officers/directors.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2022-01-12
Filed January 13, 2022, 6:59 PM ET
the Board increased its size from seven to eight directors and appointed Brittany Bradrick as a Class II director to fill the newly created vacancy.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Brittany Bradrick was appointed as Director at Dermata Therapeutics, Inc..
Action appointed
Role Director
Exact text from the filing
the Board increased its size from seven to eight directors and appointed Brittany Bradrick as a Class II director to fill the newly created vacancy.
View on SEC.gov
Source: SEC EDGAR
accession 0001654954-22-000428
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.